StemCells, Inc. Announces Strategic Realignment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
StemCells (STEM) PT Cut to $3 at Maxim Group
December 23, 2015 12:18 PM ESTMaxim Group analyst Jason Kolbert lowered his price target on StemCells (NASDAQ: STEM) to $3.00 (from $5.00) but maintained a Buy rating after the company suspended the phase II AMD (Radiant) study to focus on the spinal cord injury (SCI) trial.
Stem's management announced the decision to focus on the spinal cord injury (SCI) trial. Management will suspend the company's phase II AMD (Radiant)... MoreUPDATE: StemCells (STEM) Declines After Shares Resume Trading
December 23, 2015 8:10 AM EST(Updated - December 23, 2015 8:16 AM EST)
StemCells (NASDAQ: STEM) Declines After Shares Resume Trading
... More